Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RYTM, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Setmelanotide FDA approved Nov 2020 · Imcivree |
Bardet Biedl Syndrome (BBS) | Phase 4 · NCT07674290 | Recruiting |
| Bivamelagon | Hypothalamic Obesity | Phase 2 · NCT06046443 | Completed |
| Part C: RM-718 | Hypothalamic Obesity | Phase 1/2 · NCT06239116 | Active not recruiting |
| Part D: RM-718 | Hypothalamic Obesity | Phase 1/2 · NCT06239116 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RYTM holds $320.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.1M/quarter from operations, an estimated runway of 157.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RYTM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | Institution (13G, 5%+) | 6,666,837 | 9.62% | 2025-12-31 |
| JPMORGAN CHASE & CO. | Institution (13G, 5%+) | 3,563,667 | 5.14% | 2026-09-30 |
| Perceptive Advisors LLC | Institution (13G, 5%+) | 3,519,626 | 5.08% | 2026-03-31 |
| PRIMECAP MANAGEMENT CO/CA/ | Institution (13G, 5%+) | 3,478,669 | 5.02% | 2025-12-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 3,432,949 | 4.95% | 2026-03-31 |
| David P Meeker President and CEO, Director · +195,181 options |
Insider | 239,258 | 0.35% | 2026-09-14 |
| Hunter C Smith Chief Financial Officer · +236,714 options |
Insider | 114,024 | 0.16% | 2026-08-31 |
| Yann Mazabraud EVP, Head of International · +75,875 options |
Insider | 55,655 | 0.08% | 2026-08-12 |
| Edward T Mathers Director |
Insider | 21,168 | 0.03% | 2026-03-12 |
| Joseph Shulman Chief Technical Officer · +43,445 options |
Insider | 15,915 | 0.02% | 2026-08-13 |
| David W J Mcgirr Director · +6,015 options |
Insider | 11,712 | 0.02% | 2026-06-23 |
| Christophe Jean Director · +6,015 options |
Insider | 11,712 | 0.02% | 2026-06-23 |
Share count 69,330,906 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-03-20 | IMCIVREE | sNDA | -10.9% | -3.2% | -9.3% |
| 2025-12-20 | — | sNDA | +8.7% | +0.7% | +0.4% |
| 2025-11-07 | IMCIVREE | sNDA | -1.7% | +1.8% | -2.6% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RYTM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →